NCT00002663 - Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 1995

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

EBV-induced LymphomasEBV-associated MalignanciesTransplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

Interventions

BIOLOGICAL

Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York